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Experience with prolamine for duct obliteration 
W . - D . I L L N E R , D . A B E N D R O T H , R. L A N D G R A F , M . G O K E L and W. L A N D 
Introduction 
Clinical transplantation of the pancreas seems to 
be a promising approach to influence the late di-
abetic Syndrome. This view is corroborated by our 
recent findings in regard to the development of di-
abetic eye disease, polyneuropathy and peripheral 
microcirculation in our pancreatic transplant re-
cipients [1,85]. Mainly due to increasing experi-
ence and partly due to the introduction of cyclo-
sporine for immunosuppression [21], results of 
clinical pancreas transplantation have markedly 
improved during the last few years, both in terms 
of functional graft Performance as well as patient 
survival rates. According to the international Pan-
creas Transplant Registry, the one-year rates of 
pancreatic graft function were 20% in the period 
1978-1982 and 42% in the period 1983-1986, while 
the patient survival rates improved from 71% in 
1978 to 85% in 1986 [128]. This improvement of 
results was independent of the surgical technique 
applied for managing the exocrine System. 
In this Selected Issue we report on our experi-
ence with clinical pancreas transplantation at the 
Munich Transplant Center, with special emphasis 
on the use of prolamine for the abolishment of exo-
crine secretions. 
Principles of prolamine for duct occlusion 
The use of an alcoholic amino acid Solution ('Pro-
tamine') in order to destroy the exocrine pan-
creatic System, originates from the experimental 
work in animals by Gebhardt and Stolte [51,52]. 
They were able to demonstrate that an atrophy of 
the exocrine tissue occurs within a short time after 
injection of prolamine into the pancreatic ductal 
System, while the structure and function of the is-
lets of Langerhans remain completely unchanged 
and well preserved. The cylindric epithelium of the 
ductal System is destroyed after injection of the 
occlusive substance. After 3 or 4 days, the prolam-
ine is being lysed by immigrated leukocytes. At the 
same time, the epithelium of the duct regenerates 
and is completely restituted by the eleventh day 
following injection. Apart from these processes, an 
interstitial sialo-oedema develops with its maxi-
mum on the second to fifth day. It is replaced by 
connective tissue and results in interstitial fibrosis 
within about 3 weeks. In the mean time, atrophy 
of the acini develops along with fibrosis of the exo-
crine parenchyma. In animal experiments, these 
events are completed after about 60 days (Table 
V.9) . 
Before starting the duct injection itself, the cor-
pus-and-tail segment of the pancreas is separated 
from the spieen in vitro. The cut surface of the 
pancreatic parenchyma is sutured with absorbable 
suture material. In order to avoid contact with 
prolamine the arterial (coeliac axis) and venous 
(portal vein) vessels of the pancreatic segment are 
covered with pads. Then a hypodermic needle 
(preferably with a large lumen) is inserted in the 
pancreatic duct and fixed with a ligature. The pro-
lamine is injected under X-ray control, using a hy-
podermic syringe and room-temperature. We con-
sider the occlusion being complete as soon as the 
so-called kover-injection-effect' appears on the X -
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T A B L E V.9 
Characteristics of prolamine 
1) Solidifies rapidly in the ductal System 
2) Is microbiologically indifferent 
3) Is reabsorbed within 2 vveeks (in dogs) 
4) Leads to necrosis and regeneration of the duct epithelium 
5) Causes atrophy and fibrosis of the exocrine parenchyma 
6) Is radiopaque 
7) Does not affect the endocrine function 
ray screen, which implies that the prolamine leaves 
the ductal System and infiltrates into the paren-
chyma where small spots become visible (Fig. 
V.20). This procedure requires about 3-4 ml of 
prolamine. Finally, the needle is retracted and the 
pancreatic duct ligated. 
Patients and methods 
The first transplantation of the pancreas at our In-
stitution was performed in 1979 [82,84]. Since then, 
70 pancreas transplants have been performed. Si-
multaneous transplantation of pancreas and kid-
ney was carried out in 62 patients with type 1 di-
abetes. Two patients had to be retransplanted, and 
six non-uremic diabetic patients received only a 
Fig. V.20. Procedure of duct injection with prolamine. 
The duct injection is considered to be efficient when first 
signs of over-injection appear by X-ray. 
T A B L E V.10 
Pancreas transplantation with duct occlusion in type 1 diabe-
tes* 
No. of No. of pancreas 
patients transplants 
Pancreas plus kidney 62 62 
1979- 1981 3 
1981 - August 1984 31 
September 1984- March 1987 28 
Pancreas alone 6 6 
Pancreatic retransplantation 2 
Total 68 70 
Transplant Center Munich, March 1987. 
pancreas transplant (Table V.10). 
In all cases, transplantation of a duct-occluded 
segment of the pancreas was performed, and pro-
lamine (Ethibloc®) was used for duct occlusion. 
Initially, the graft was placed partly extra- and 
partly intra-abdominally, as described by Duber-
nard et al. [41]. As of the end of 1984, the graft was 
placed strictly intra-abdominally along the colon 
ascendens, with a short (3 days) period of subse-
quent postoperative abdominal lavage. Further-
more, our immunosuppressive and anticoagula-
tive regimens were adapted in 1984, in order to 
guarantee a high immunosuppressive index and to 
avoid the early irreversible thrombosis of the 
splenic vein (Table V . l l ) . 
T A B L E V . l l 
The present regimen of pancreatic transplantation* 
Surgical technique: Graft completely intraperitoneal 
Continuous irrigation (3 days) 
Immunosuppression: Quadruple drug induction therapy 
Triple drug therapy for 6 months 
Maintenance therapy with cyclosporine 
and azathioprine 
Anticoagulation: Rheomacrodex® 
Low dose heparin 
"Started in September 1984. 
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Graft and patient survival rates 
It appears justified to present our results of com-
bined pancreas and kidney transplantation by time 
era, in analogy to the reports from the interna-
tional Pancreas Transplant Registry [128]. These 
results are graphically illustrated in Fig. V.21 and 
V.22. 
The results of transplants performed during the 
period from 1981 until August 1984 were as fol-
lows. The pancreatic function rate was 40% (30 
months post-transplant) and the renal function rate 
was 36% (39 months post-transplant) after simul-
taneous pancreas and kidney transplantation. The 
corresponding patient survival rate was 83%. 
The results of transplants performed during the 
subsequent period from September 1984 until 
March 1987 had conspicuously improved. The 30-
month function rate was 74% for the pancreas 
transplants and 71% for the kidney transplants. 
The patient survival rate was 93%. During this lat-
ter period we lost only one patient; this was a 54-
year-old male who died with a functioning kidney 
Kidney survival ra te 
100 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
10 
Sept. 1 9 8 4 - March 1987 
1981 - 1 9 8 4 
- • 3 6 °/o 
~0 3 6 9 12 15 18 21 24 27 3 0 33 3 6 3 9 
Months 
Fig. V.22. Kidney graft survival rate in combined pan-
creas and renal allotransplantation according to differ-
ent periods (Cutler-Ederer formula). Since September 
1984 some modifications were used. 
9 months after simultaneous grafting. In this pa-
tient, death was caused by diabetic complications 
and not by the transplantation itself. 
Complications with prolamine 
P a n c r e a s s u r v i v a l r a t e 
S e p t . 1984 - M a r c h 1987 n = 26 
1981 - 1 9 8 4 n = 3 2 
4 0 °/o 
0 3 6 9 12 15 18 21 24 27 30 
M o n t h s 
Fig. V.21. Pancreas survival rate in simultaneous pan-
creas and kidney transplantation according to different 
periods, using some modifications since September 1984 
(Cutler-Ederer formula). 
In contrast to the experimental findings in animals 
[51,52], we have noted a delayed destruction and 
atrophy of the exocrine parenchyma with histolog-
ical examination of our clinical material (Fig. 
V.23). This explains our Observation, that about 
50% of the prolamine-occluded segmental grafts 
maintain a marked residual exocrine function and 
develop a cutaneous pancreatic fistula [74]. This 
residual exocrine function with fistulation may last 
during varying periods of time from 8 weeks as a 
minimum to up to 8 months. The additional med-
icamentous blocking of the exocrine function with 
somatostatin appears to influence only the inten-
sity but not the duration of the residual exocrine 
function. The chance of secondary bacterial infec-
tion increases with longer duration of exocrine fis-
tulation, and we call such secondarily infected fis-
tulae 4complicated pancreatic fistula'. Their proper 
treatment presents a heavy challenge to the sur-
geon, since not only the function of the graft but 
also the life of the recipient may depend upon the 
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outcome of treatment. As shown in Table V.12, the 
incidence of pancreatic fistulae was not reduced by 
placing the pancreatic transplant completely intra-
abdominally instead of partly intra- and partly ex-
tra-abdominally. Therefore, we now apply a short 
time (about 3 days) continuous lavage of the ab-
domen in order to remove the highly active amy-
lase/lipase secretions (which are especially active 
in the early post-transplant phase). This proce-
dure has been elected in order to: 1) prevent adhe-
sions, and 2) minimize the intra-abdominal vol-
T A B L E V.12 
Incidence of pancreatic fistula using prolamine 
Time era No. of Incidence of fistulae 
grafts No. % 
1979 - August 1984 25 13 52 
September 1984- March 
1987 26 12 46 
ume of these secretions, which probably serve as 
an ideal 'culture medium* for bacteriae. This mod-
ified surgical technique appears to reduce the in-
cidence of local complications caused by compli-
cated pancreatic fistulae and, consequently, to 
reduce the incidence of pancreatic graft loss (Ta-
ble V.13). The question why every other recipient 
of a prolamine-occluded segmental pancreas graft 
maintains residual exocrine function during vary-
ing periods of time remains unanswered and will 
be the subject of further studies. 
T A B L E V.13 
Graft loss due to complicated pancreatic fistulae 
Time era No. of 
grafts 
Graft loss 
No. % 
1979-August 1984 25 5 20 
September 1984 - March 
1987 26 2 8 
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Metabolie investigations 
A l l of the successfully transplanted patients have 
normal H b A l levels and are independent of insu-
lin. Normal oral glucose tolerance tests (as judged 
by the WHO-criteria) were found in 63% of the 
cases, but 37% had impaired utilization of glu-
cose. Both in recipients with normal as well as in 
those with impaired oral glucose tolerance, basal 
insulin, C-peptide and glucagon levels are some-
what higher than in normal controls. Only patients 
with an impaired glucose tolerance show a delay in 
glucose-provoked insulin response and in C-pep-
tide response after arginine Stimulation. However, 
glucagon values after arginine Stimulation are sim-
ilar in patients with either normal or impaired glu-
100g glucose p.o. 15g arginine i.v. 
0 30 60 12Ö 150 180 
Minutes 
Fig. V.24. Behavior of blood glucose and serum insulin 
during oral glucose load and i.v. arginine Stimulation (^) 
according to different periods post-transplant in recipi-
ents of simultaneously transplanted pancreas and kid-
ney grafts. 
cose tolerance. One of the most important obser-
vations with regard to the technique of duct 
occlusion is that no deterioration of endocrine graft 
function was found to occur with time. The mean 
values of blood glucose levels and insulin re-
sponses after glucose loading and arginine Stimu-
lation are similar at 4 and 27 months post-trans-
plant. As shown in Fig. V.24, we even found some 
indication (although not statistically significant) for 
improvement of endocrine graft Performance with 
time. 
These data clearly demonstrate that, at present, 
we have no reason to suspect a deleterious influ-
ence of duct occlusion with prolamine on the en-
docrine function of segmental pancreatic grafts. 
Our clinical findings are corroborated by the pre-
vious experimental studies of Gebhardt et al. 
[51,52] and Land et al. [82]. 
Concluding remarks 
The results of simultaneous transplantation of the 
pancreas and the kidney using the duct-occlusion 
technique with prolamine have been improved by 
modifications of: 1) the surgical technique; 2) the 
immunosuppressive regimen; and 3) the method 
of anticoagulant prophylactic medication. Seven 
years of experience with prolamine for duct occlu-
sion have shown that the endocrine function of 
duct-occluded segmental pancreatic allografts re-
mains unchanged with time. Neither histologic nor 
metabolic examinations could support the Sugges-
tion that fibrosis of the exocrine parenchyma may 
contribute substantially to eventual endocrine graft 
failure. The questions why about 50% of the duct-
occluded grafts maintain a transient residual func-
tion of the exocrine System, and why 63% of the 
patients have a normal oral glucose tolerance while 
37% have not, remain unanswered at the present 
time. 
It should be emphasized that segmental trans-
plantation of the pancreas using duct occlusion with 
prolamine leads to: 1) a drastic decrease in mor-
tality: 2) acceptable morbidity; 3) a relatively high 
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rate of adequate graft function; 4) a high rate of 
psycho-social rehabilitation; and 5) a marked pre-
vention of late diabetic Syndromes. 
The results of long-term studies will have to be 
awaited in order to decide upon the question if it 
is possible to obtain long-lasting prevention of late 
complications of diabetes by means of successful 
pancreatic transplantation. 
